A new test for diagnosing Alzheimer’s Disease: pTau217 protein | Canadian Medical

A new test for diagnosing Alzheimer’s Disease: pTau217 protein

News

20. 11. 2026

Persistent deterioration in memory, orientation or planning ability should be addressed early. If a neurologist suspects Alzheimer’s disease, the diagnostic assessment can now be supplemented with a pTau217 blood test, newly available at Canadian Medical. The neurologist will assess whether the test is appropriate for the patient, discuss the results following the examination and recommend the next steps.

What is Alzheimer’s Disease and how does it manifest?

Alzheimer’s disease (AD) is the most common type of dementia in our population. It involves progressive, irreversible damage to nerve cells in the brain, known as neurodegeneration.

The disease develops gradually, and its prevalence increases with age. While the text reports an annual figure of 3% among people aged 65–74, the figures given for those aged 75–84 and over 85 are 19% and up to 47%, respectively.

Initially, the disease manifests as subtle, mild impairment of cognitive functions (memory, orientation, planning and judgement), without yet interfering with everyday activities or the patient’s independence. This is known as mild cognitive impairment (MCI). Although the difficulties are relatively mild, they are not typical for the person’s age. Patients may notice them themselves, or family members or colleagues may draw attention to them. Ideally, Alzheimer’s disease should be diagnosed at this early stage.

At the subsequent stage of dementia, the disease begins to interfere with the patient’s ability to carry out everyday activities and live independently. Memory is impaired (initially short-term and later long-term memory), as is orientation in space (including orientation to oneself and misplacing objects at home). Speech problems arise, such as forgetting simple words and replacing them with incorrect ones. Judgement and insight deteriorate, and abstract thinking becomes difficult (numbers, bills, payment slips and the functions of familiar objects such as keys). Changes in mood, behaviour (intense emotional reactions, depression and loss of initiative) and personality may also occur. According to the source text, untreated disease leads to death after an average disease duration of nine years.

In Alzheimer’s disease, abnormalities occur in the production and processing of certain proteins and their components (beta-amyloid and tau protein). These accumulate in the brain, interfere with communication and normal functioning between nerve cells, and ultimately lead to their death.

How is Alzheimer’s Disease diagnosed?

The first and most important step in diagnosing AD is to seek medical advice promptly when problems arise. We would not ordinarily suspect early dementia in a 30-year-old who occasionally forgets a task or a piece of information while overwhelmed by work, stress and inadequate sleep. By contrast, similar symptoms occurring daily in someone over 50 should not be overlooked. The first point of contact is usually a general practitioner. For people aged 65–80, basic cognitive testing is already included in routine preventive check-ups every two years.

If cognitive impairment is suspected, the general practitioner will usually refer the patient to a specialist (a neurologist, psychiatrist or gerontologist—a specialist in ageing and the health issues of older people). The first priority is to rule out treatable causes of dementia, such as thyroid disorders or conditions affecting cerebrospinal fluid circulation, including normal-pressure hydrocephalus. More detailed cognitive tests, brain imaging (computed tomography, CT, or magnetic resonance imaging, MRI) and blood tests are then performed.

A new option in 2026 is a blood test measuring a protein called pTau217 (tau protein phosphorylated—that is, chemically modified—at amino acid position 217). According to the source text, this test has sensitivity and accuracy exceeding 90% and can help identify early Alzheimer’s disease and distinguish it from other types of dementia. Despite requiring only a blood sample, its diagnostic performance can be comparable to specialised cerebrospinal fluid testing (obtained by lumbar puncture) and positron emission tomography (PET) brain imaging, which have traditionally been used for further diagnostic clarification.

Who is the new pTau217 diagnostic test intended for, and what does it involve?

The test is intended for people over 55 who experience cognitive difficulties and/or in whom cognitive impairment is suspected based on cognitive tests performed by a general practitioner or specialist.

Testing may also be considered for younger people with cognitive impairment and a family history of early-onset AD (diagnosed before the age of 60 in a close relative).

The test is not intended for asymptomatic individuals or for young people in whom Alzheimer’s dementia is not suspected.

At Canadian Medical, the indication for the blood test, an explanation of its benefits and the subsequent interpretation of the results are provided exclusively by a neurologist.

The test involves taking one tube of blood. We recommend arriving for the blood draw on an empty stomach and ensuring adequate fluid intake—300–500 ml of plain water before the morning appointment. Results are available in approximately 10–14 days.

The result falls into one of three categories, with a high degree of accuracy:

  • Negative – the likelihood of AD is minimal.
  • Borderline – the possibility of AD developing in the coming years cannot be completely ruled out, but the result does not currently indicate early disease.
  • Positive – strongly suggests a diagnosis of AD.

As of November 2026, the test is not covered by public health insurance. At Canadian Medical, it is available for clients who meet the clinical criteria for testing at a price of CZK 4,900.

What Are the Next Steps and Treatment Options Based on the Results?

Treatment options for AD remain limited, as there is currently no causal treatment capable of completely curing the disease. This should be borne in mind before undergoing testing.

In the event of a negative pTau217 result, and more generally for the prevention of neurodegenerative brain diseases, we recommend:

  • Regular daily physical activity (walking at least 3,000 steps a day, ideally 8,000–10,000).
  • Daily cognitive activities (training short-term, long-term, visual and auditory memory), with an emphasis on maintaining social contact among older adults (“not being alone”).
  • Helpful smartphone applications, such as Terrapino and Brainmondo.
  • A healthy Mediterranean-style diet with plenty of vegetables and fruit, limited fat intake and sufficient vitamin D.
  • Reducing excess body weight, where applicable.
  • Abstaining from alcohol.

In the event of a borderline pTau217 result, in addition to the measures listed above, dietary supplements containing Ginkgo biloba may be recommended, according to the source text.
In the event of a positive pTau217 result, the next steps depend on the degree of cognitive impairment.

Patients in the early stage of the disease, known as MCI (mild cognitive impairment, with full independence preserved), should be referred to a specialist centre for cognitive disorders. There, modern disease-modifying biological treatments for AD (lecanemab or donanemab) may be considered, or the patient may be offered participation in a clinical trial of new AD treatments. Both medicines have been authorised in the Czech Republic, although reimbursement had not yet been established as of 2026.

For more advanced stages involving dementia, medicines such as donepezil, rivastigmine and memantine are used to slow symptomatic progression.

Comprehensive care provided by a specialist (neurologist, psychiatrist or gerontologist) together with a general practitioner is essential for patients with dementia, both for the patients themselves and to support their closest caregivers.

Do not hesitate to consult a doctor if you are over 50 and feel that your memory is deteriorating, or if someone else has drawn your attention to such a problem. Think of your parents, too, and accompany them to a doctor promptly if their memory, speech, orientation or planning ability deteriorates significantly. These may be signs of Alzheimer’s disease.

 

MUDr. Eva Krasulová, Ph.D., chief physician of neurology, Canadian Medical

Articles and news

News

Notice: Temporary lift service disruption at the YMCA clinic

News

Canadian Medical is an accredited and certified workplace

News

Nutrilon infant formula Rrcall: How to identify affected products and when to seek medical advice

News

Flu vaccination is now available

News

Autumn is here. Stay at your best

Article

Canadian Medical partners with Alžběta Jungrová’s exhibition and new book

News

Canadian Medical becomes a partner of the 60th KVIFF

News

Outpatient varicose vein surgery

News

Do you want to learn how to correctly provide first aid to your child?